Quick Links: Skip to main page content
Skip to Search
Skip to Topics Menu
Skip to Common Links
U.S. Food & Drug Administration
Follow FDA
En Español
Search FDA
Home
Food
Drugs
Medical Devices
Radiation-Emitting Products
Vaccines, Blood & Biologics
Animal & Veterinary
Cosmetics
Tobacco Products
New Pediatric Labeling Information Database - Detail
FDA Home
Pediatrics
New Pediatric Labeling Information Database
Detail
-
Please note:
JavaScript must be enabled for this application to work properly.
Check your settings
if you are unsure if your JavaScript is enabled.
Pediatric Labeling Date:
05/05/2008
Trade Name:
Levaquin Tablets, 250 mg, 500 mg, and 750 mg Levaquin Oral Solution, 25 mg/mL Levaquin Injection and Levaquin Injection, 5 mg/mL
Generic Name or Proper Name (*):
levofloxacin levofloxacin in 5% dextrose injection
Indications Studied:
Reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis (inhalational anthrax post-exposure)
Label Changes Summary:
New indication Dosing information provided for children less than and greater than 50 kg Efficacy is based on plasma concentrations achieved in humans, a surrogate endpoint reasonably likely to predict clinical benefit, and animal studies were used to evaluate survival; the product has not been tested in humans for the post-exposure prevention of inhalation anthrax Safety in pediatric patients treated for more than 14 days has not been studied Long-term safety data, including effects on cartilage, following administration in pediatric patients is limited Due to possible side effects, use is not recommended for pediatric patients except in the prevention of anthrax after inhalational exposure Pharmacokinetics were investigated in pediatric patients 6 months to 16 years old
PREA(P):
P
Sponsor:
Ortho-McNeil-Janssen Pharmaceutical, Inc.
NNPS:
TRUE'
Therapeutic Category:
Antibiotic
-
-